[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Greater Cannabis CO (GCAN)

Greater Cannabis CO (GCAN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Greater Cannabis CO

www.gammacan.com

Sector:

N/A

INDUSTRY GROUPING:

N/A

Description:

Gammacan International, Inc. was incorporated under the laws of the state of Delaware on October 6, 1998 under the name of San Jose International, Inc. On August 19, 2004, the Company changed the name of its company to Gammacan International, Inc. in the State of Delaware. With the acquisition of the Intellectual Property, the Company is now focused on the commercialization of an anti-cancer immunotherapy that appears to be effective in reducing the metastatic spread of a wide range of cancers. The Company's proposed treatment will be based on intravenous immunoglobulin or IVIG, a safe, minimally-toxic human plasma-based product, currently used to treat a variety of immune deficiencies and autoimmune diseases, and replace the antibodies in people who are unable to produce them. The Company's initial focus over the next several years is to demonstrate efficacy of IVIG cancer immunotherapy in human clinical trials. IVIG immunotherapy will require regulatory approval before being commercially marketed for human therapeutic use. Clinical trials generally include three phases that together may take several years to complete. Phase 1 clinical studies are primarily conducted to establish safety. Phase 2 studies are designed to determine preliminary efficacy. Phase 3 studies are conducted to optimize therapeutic efficacy in a statistical manner at the levels of optimal dose, method of delivery into the body or route, and schedule of administration. Once clinical trials are completed successfully, products may receive regulatory approval.

Key Statistics

Overview:

Short Interest, K 5
Short Float 0.00%
Days to Cover 1.00
Short Volume Ratio 0.17

Financials:

Annual Sales, $ 0 K
Annual Net Income, $ 0 K

Growth:

1-Year Return -52.13%
3-Year Return -75.83%
5-Year Return -98.60%

Per-Share Information:

Next Earnings Date 12/31/69
EPS Growth vs. Prev Qtr 0.00%
EPS Growth vs. Prev Year 0.00%
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Dividend Payout Ratio 0.00%

GCAN Ratios

Ratio
Price/Earnings ttm N/A
Price/Earnings forward 0.00
Price/Earnings to Growth 0.00
Return-on-Equity % -2.13%
Return-on-Assets % -1.65%
Profit Margin % 0.00%
Debt/Equity N/A
Price/Sales N/A
Price/Cash Flow 0.00
Price/Book 0.00
Book Value/Share N/A
Interest Coverage N/A
60-Month Beta N/A
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.